



Ministry of Health, Welfare and Sport

EunetHTA Conference 'HTA in cross-border healthcare in Europe'

Gdansk

Hugo Hurts

Director, Department of
Pharmaceutical Affairs and Medical
Technology

Ministry of Health, Welfare and Sport,
The Netherlands



Use of Health Technology Assessments

- Reimbursement of medical technologies
- Role of HTA in the decision-making progress
- European HTA assessments

BACK UP SLIDES





**High disease burden and
medical need**

Accessibility

versus

Affordability

Innovation

**High costs and
uncertain
outcomes**

Challenges new generation of 'expensive' hospital drugs


- Affordability
 - Strong expenditure growth
 - High costs per patient
 - Limited cost containment instruments (central and decentral)
- Healthcare benefit scheme coverage decision-making
 - Complex, limited information, high importance for patients and industry
 - Benefit scheme decision-making: 'yes/no'
 - HTA knowledge and labour intensive



- Focus on high (financial) risks
- Focus on new 'expensive' hospital drugs
- Quick- but conditional - patient access
- Outcome based schemes operational since 2006
- Finance based schemes to be introduced in 2013, alongside outcomes based schemes: learn from other member states!


Pharmaceutical market: different segments, different dynamics, different policy approach

- **New patented products**
- Market monopoly – no price competition
- Rational use not yet covered by prescription guidelines
- Growing expenditure (€ 1 - 1,5 billion)




- **Older – often non-patented - products**
- (price)competition
- Rational use implemented
- Lowering expenditure (>€ 4,5 billion)

Government intervention



Market forces

CONDITIONAL REIMBURSEMENT 'EXPENSIVE' HOSPITAL DRUGS from 2012 onwards



Red: to be introduced from 2013 onwards

* Incremental cost-effectiveness ratio